Spero Therapeutics Inc (NAS:SPRO)
$ 1.03 0.0861 (9.12%) Market Cap: 56.15 Mil Enterprise Value: -20.21 Mil PE Ratio: 12.88 PB Ratio: 0.85 GF Score: 39/100

Spero Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference Transcript

May 13, 2020 / 05:00PM GMT
Release Date Price: $11.7 (-2.50%)
Jason Matthew Gerberry
BofA Merrill Lynch, Research Division - MD in US Equity Research

Good day, everybody. Thank you so much for dialing in or joining into the afternoon sessions of Bank of America's Annual Health Care Conference. My name is Jason Gerberry. I cover specialty pharma and small-, mid-cap biotech at Bank of America. And I am pleased to be introducing our next company presenter, Spero Therapeutics. And I'm introducing Ankit Mahadevia, CEO. Spero, for those of you who don't know, is a development stage company with a focus in the anti-infective and antibiotics space. So Ankit has some slides. And so I'm going to turn it over to him. And at the end, I think we have some time for some questions.

So Ankit, all yours.

Ankit Mahadevia
Spero Therapeutics, Inc. - Co-Founder, CEO, President & Director

Thank you, Jason, and to the Bank of America team for the opportunity to share our progress. On Slide 2 are our forward-looking statements. And on Slide 3 -- I'd guide the folks on the webcast, too. And we appreciate the opportunity, Jason. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot